Uploading C:\Program Files\Stnexp\Queries\10580480d.str

L15 STRUCTURE UPLOADED

=> d L15 HAS NO ANSWERS L15 ST

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

Structure attributes must be viewed using STN Express query preparation.

=> s 115 sss

SAMPLE SEARCH INITIATED 14:48:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10587 TO ITERATE

18.9% PROCESSED 2000 ITERATIONS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 205572 TO 217908

L16 1 SEA SSS SAM L15

=> s 115 sss full

PROJECTED ANSWERS:

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y FULL SEARCH INITIATED 14:48:21 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 211795 TO ITERATE

1 TO

100.0% PROCESSED 211795 ITERATIONS

205 ANSWERS

1 ANSWERS

SEARCH TIME: 00.00.04

L17 205 SEA SSS FUL L15

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 192.03 662.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION -9.35 CA SUBSCRIBER PRICE 0.00

FILE 'CAPLUS' ENTERED AT 14:48:31 ON 08 SEP 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2010 VOL 153 ISS 11 FILE LAST UPDATED: 7 Sep 2010 (20100907/ED) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 117L18 47 L17

=> s 118 and Py<2004 24051605 PY<2004 27 L18 AND PY<2004 T₁19

=> s 118 and Py<2003 22999285 PY<2003

24 L18 AND PY<2003 L_{20}

=> d 119 1-10 ibib abs hitstr THE ESTIMATED COST FOR THIS REQUEST IS 58.10 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y) / N: y

L19 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:535052 CAPLUS

DOCUMENT NUMBER: 139:292132

TITLE: Design, synthesis and antimalarial activity of novel,

SOURCE:

quinoline-Based, zinc metallo-aminopeptidase

inhibitors

AUTHOR(S): Flipo, Marian; Florent, Isabelle; Grellier, Philippe;

Sergheraert, Christian; Deprez-Poulain, Rebecca
CORPORATE SOURCE: Institut Pasteur et Institut de Biologie de Lille,
Universite de Lille 2, UMR CNRS 8525, Lille, Fr.

Bioorganic & Medicinal Chemistry Letters (2003

), 13(16), 2659-2662

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:292132

AB PfA-M1, a neutral zinc aminopeptidase of Plasmodium falciparum, is a new potential target for the discovery of antimalarials. The design and synthesis of a library of 45 quinoline-based inhibitors of PfA-M1 is reported. The best inhibitor displays an IC50 of 854 nM. The antimalarial activity on a CQ-resistant strain and the specificity towards mammalian aminopeptidase N are also discussed. Compds. thus prepared and evaluated included N1-hydroxy-N2-(2-methylpropy1)-N2-(4-quinoliny1)propanediamide, N1-hydroxy-N2,2-bis(2-methylpropy1)-N2-(4-quinoliny1)propanediamide and 2-amino-N1-hydroxy-N2-(2-methylpropy1)-N2-(4-quinoliny1)propanediamide. These compds. were analogs of N-(cyclopropylmethy1)-N-(4-quinoliny1)- β -alaninamide.

IT 608520-26-9P 608520-27-0P 608520-29-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design, preparation and antimalarial activity of quinoline-based zinc metallo-aminopeptidase inhibitors)

RN 608520-26-9 CAPLUS

CN Propanediamide, 2-amino-N1-[3-[4-[3-[(7-chloro-4-quinolinyl)amino]propyl]-1-piperazinyl]propyl]-N3-hydroxy-N1-(2-methylpropyl)- (CA INDEX NAME)

RN 608520-27-0 CAPLUS

CN Propanediamide, N1-[3-[4-[3-[(7-chloro-4-quinolinyl)amino]propyl]-1-piperazinyl]propyl]-N3-hydroxy-N1-(2-methylpropyl)- (CA INDEX NAME)

RN 608520-29-2 CAPLUS

CN Propanediamide, N1-[3-[4-[3-[(7-chloro-4-quinolinyl)amino]propyl]-1-piperazinyl]propyl]-N3-hydroxy-N1,2-bis(2-methylpropyl)- (CA INDEX NAME)

OS.CITING REF COUNT:

23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:485895 CAPLUS

DOCUMENT NUMBER: 139:223711

TITLE: Novel inhibitors of procollagen C-Proteinase. Part 2:

glutamic acid hydroxamates

AUTHOR(S): Robinson, L. A.; Wilson, D. M.; Delaet, N. G. J.;

Bradley, E. K.; Dankwardt, S. M.; Campbell, J. A.; Martin, R. L.; Van Wart, H. E.; Walker, K. A. M.;

Sullivan, R. W.

CORPORATE SOURCE: CombiChem Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003

), 13(14), 2381-2384

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:223711

AB Glutamic acid derived hydroxamates were identified as potent and selective inhibitors of procollagen C-proteinase, an essential enzyme for the processing of procollagens to fibrillar collagens. Such compds. have potential therapeutic application in the treatment of fibrosis.

IT 279255-52-6P 591766-04-0P 591766-06-2P

591766-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and structure-activity relationship of glutamic acid hydroxamates as novel inhibitors of procollagen C-Proteinase)

RN 279255-52-6 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N5-(2-cyanoethyl)-N1-hydroxy-N5-(phenylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-04-0 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)](4-methoxyphenyl)sulfonyl]amino]-N5,N5-diethyl-N1-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-06-2 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)](4-methoxyphenyl)sulfonyl]amino]-N1-hydroxy-N5-(2-phenylethyl)-N5-(phenylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 591766-07-3 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)](4-methoxyphenyl)sulfonyl]amino]-N5-(2-cyanoethyl)-N1-hydroxy-N5-(3-pyridinylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS

RECORD (13 CITINGS)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:477672 CAPLUS

DOCUMENT NUMBER: 139:350613

TITLE: Simple preparation of N-benzyl- β -aminohydroxamic

acids by 1,3-dipolar cycloaddition of nitrones

AUTHOR(S): Chevrier, Carine; Defoin, Albert

CORPORATE SOURCE: Laboratoire de Chimie Organique et Bioorganique UMR

7015, Ecole Nationale Superieure de Chimie de

Mulhouse, Universite de Haute-Alsace, Mulhouse, 68093,

Fr.

SOURCE: Synthesis (2003), (8), 1221-1224

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:350613

AB β -Aminohydroxamic acids 6a-d are prepared in 4 steps and 30-45% overall yield from nitrones 1a-d by 1,3-dipolar cycloaddn. with Ph vinyl ether, N-benzylation, thermal rearrangement, and nucleophilic substitution of the formed Ph ester with hydroxylamine. Nitrones included

3,4-dihydro-2H-pyrrole 1-oxide, 2,3,4,5-tetrahydropyridine 1-oxide,

N-(butylidene)-1-butanamine N-oxide,

(3R, 4R)-3, 4-dihydro-3, 4-bis(methoxymethoxy)-2H-pyrrole. Hydroxamic acids thus prepared included N-hydroxy-1-(phenylmethyl)-2-pyrrolidineacetamide, N-hydroxy-1-(phenylmethyl)-2-piperidineacetamide,

3-[butyl(phenylmethyl)amino]-N-hydroxyhexanamide,

(-) - (2R, 3R, 4R) -N-Hydroxy-3, 4-bis (methoxymethoxy)-1-(phenylmethyl)-2-pyrrolidineacetamide,.

IT 618107-08-7P, 3-[Butyl(phenylmethyl)amino]-N-hydroxyhexanamide

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-benzyl- β -aminohydroxamic acids by 1,3-dipolar cycloaddn. of nitrones)

RN 618107-08-7 CAPLUS

CN Hexanamide, 3-[butyl(phenylmethyl)amino]-N-hydroxy- (CA INDEX NAME)

```
CH2-Ph
                N−Bu−n
{\tt HO-NH-C-CH_2-CH-Pr-n}
```

OS.CITING REF COUNT: THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

2002:275960 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 136:310184

TITLE: Preparation of hydroxamic acid peptide deformylase

inhibitors as antibacterial agents

INVENTOR(S): Chong, Lee; Frechette, Roger; Scott, Carole; Tester,

Richard; Smith, Whitney; Chiba, Katsumi; Sakamoto,

Masatoshi; Gluchowski, Charles

PATENT ASSIGNEE(S): Questcor Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 171 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	PATENT NO.		KIND DATE			APPLICATION NO.				NO.	DATE						
	2002 2002		-		A2 A3		2002 2003			WO 2	001-	US29	 926		2	0010	924 <
NO	W:	AE, CO, GM, LS, PT,	AG, CR, HR, LT, RO,	AL, CU, HU, LU, RU,	AM, CZ, ID, LV, SD,	AT, DE, IL, MA, SE,	AU, DK, IN, MD, SG,	AZ, DM, IS, MG,	DZ, JP, MK,	EC, KE, MN,	EE, KG, MW,	ES, KP, MX,	FI, KR, MZ,	GB, KZ, NO,	GD, LC, NZ,	GE, LK, PH,	GH, LR, PL,
	R₩:	GH, KZ, IE,	GM, MD, IT,	KE, RU, LU,	TJ, MC,	MW, TM, NL,	MZ, AT, PT, SN,	BE, SE,	CH, TR,	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,
	GQ, GW, ML, AU 2002030385 RIORITY APPLN. INFO.:									AU 2 US 2 US 2 WO 2	000- 001-	2349 7618	67P 50		P 2 A 2	0000	118
OTHER SO	THER SOURCE(S):			MAR:	PAT	136:	3101	84									

AΒ Hydroxamic acid derivs. of peptides and peptidomimetics of formulas I, II, and III [wherein Z = NHOH or ORa; Ra = alkyl or a biocleavable moiety; X = CO or SO2; Y = (un)substituted heteroalkyl or heterocyclyl; R1 = (un) substituted (cyclo) alkyl, aryl, heterocyclyl, or heteroalkyl; R2R3 = 4-7 membered (un)substituted heterocycle; R2R4 = ring formed through a CH2CH2 linkage; or R2 = Me; or R3 = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; or R4 = H or (un)substituted (hetero)alkyl, aryl, or heterocyclyl; R5 and R6 = independently H, NO2, NH2, NHCOH, NHCOCH3, NHSO2CH3, or (un) substituted CH2NH-(hetero)alkyl or CH2NH-heterocyclyl; one of R7 or R8 = CHR10CONHOH; one of R7 or R8 = (un)substituted (hetero)alkyl, (alkyl)heterocyclyl, or alkylaryl; R9 and R10 = independently H or (un) substituted (hetero) alkyl, (alkyl) heterocyclyl, or alkylaryl] were prepared as peptide deformylase (Fe-PDF) inhibitors for treating various bacterial infections. For example, 3-pyrrolidinol was added to tert-Bu (R)-(2-pentyl) succinate mono(N-hydroxysuccinimide) ester to give the amide (68%). Treatment with 20% TFA/DCM, followed by MeOH, benzene, and TMSN2 in hexanes, to afford the Me ester (90%). The pyrrolidinol was coupled with 4-methoxyphenylisocyanate and the ester converted to the hydroxamic acid (IV) using NH2OH●HCl. The latter inhibited E. coli Fe-PDF with IC50 of 9 nM and showed selectivity for Fe-PDF vs. thermolysin with a selectivity index of 30,000. Thus, I, II, and III are useful as antibiotics against a broad range of infectious disease in animals and humans.

IV

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

409129-82-4P

TOh 08/09/2010

409129-81-3P

409129-80-2P

409129-83-5P

ΙT

(Uses)

(peptide deformylase inhibitor; preparation of hydroxamic acid derivs. of peptides and peptidomimetics as peptide deformylase inhibitors for treatment of infectious diseases)

RN 409129-80-2 CAPLUS

CN Butanediamide, N4-hydroxy-N1-(2-hydroxyethyl)-2-pentyl-N1-(phenylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Me (CH₂) 4 R
$$\stackrel{\text{H}}{\text{N}}$$
 OH

RN 409129-81-3 CAPLUS

CN Butanediamide, N4-hydroxy-N1, N1-bis(2-hydroxyethyl)-2-pentyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Me (CH₂)
$$_{4}$$
 R OH HO NO HO

RN 409129-82-4 CAPLUS

CN Butanediamide, N1-[2-(3,4-dimethoxyphenyl)ethyl]-N4-hydroxy-N1-methyl-2-pentyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 409129-83-5 CAPLUS

CN Butanediamide, N4-hydroxy-N1-(2-hydroxyethyl)-N1-methyl-2-pentyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

Me (CH₂)
$$_{4}$$
 R OH NO OH Me

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS

RECORD (11 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:152517 CAPLUS

DOCUMENT NUMBER: 139:91098

TITLE: Transition metal complexes of two new

imino-dihydroxamic acids. [Erratum to document cited

in CA136:43578]

AUTHOR(S): Santos, M. Amelia; Grazina, Raquel; Pinto, Margarida;

Farkas, Etelka

CORPORATE SOURCE: Centro de Quimica Estrutural, Instituto Superior

Tecnico, Lisbon, 1049-001, Port.

SOURCE: Inorganica Chimica Acta (2002), 329, 155

CODEN: ICHAA3; ISSN: 0020-1693

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal LANGUAGE: English

AB A revised version of Table 1 is given to correct 3 standard deviation values

IT 380371-98-2D, transition metal complexes 380372-00-9D

, transition metal complexes

RL: CPS (Chemical process); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); FORM (Formation,

nonpreparative); PROC (Process)

(transition metal complexation with imino-dihydroxamic acids (Erratum))

RN 380371-98-2 CAPLUS

CN Propanamide, 3,3'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

RN 380372-00-9 CAPLUS

CN Butanamide, 4,4'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

$$\begin{array}{c|cccc} & & & \text{CH}_2\text{-Ph} & \text{O} \\ & & & & \parallel \\ & & & & \parallel \\ \text{HO-NH-C-} & \text{(CH}_2) & 3-\text{N--} & \text{(CH}_2) & 3-\text{C--NH-OH} \end{array}$$

IT 380371-98-2P 380372-00-9P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(transition metal complexation with imino-dihydroxamic acids (Erratum))

RN 380371-98-2 CAPLUS

CN Propanamide, 3,3'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

RN 380372-00-9 CAPLUS

CN Butanamide, 4,4'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

O CH₂-Ph O
$$\parallel$$
 HO-NH-C-(CH₂)3-N-(CH₂)3-C-NH-OH

L19 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:713343 CAPLUS

DOCUMENT NUMBER: 135:272894

TITLE: Preparation of β -amino acid derivatives as

inhibitors of matrix metalloproteases and TNF- α Duan, Jingwu; King, Bryan W.; Decicco, Carl;

INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl Maduskuie, Thomas P., Jr.; Voss, Matthew E.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 483 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIN	D	DATE			APPLICATION NO.					DATE			
WO 2001				A2 A3		 2001 2002			WO 2	001-	US83:	36		2	0010	315 <	
	AT, JP,	AU, KR,	BR, LT,	CA, LU,	CH, LV,	CN,	CZ, PL,	PT,	RO,							•	
RW	AM, : AT,	•	BY, CH,	•	•	•	•	•		GB,	GR,	IE,	IT,	LU,	MC,	NL,	

CN

```
PT, SE, TR
     CA 2400168
                                20010927
                                         CA 2001-2400168
                                                                   20010315 <--
                         Α1
     AU 2001050850
                                20011003
                                           AU 2001-50850
                                                                   20010315 <--
                         A
     EP 1263756
                         A2
                                20021211
                                           EP 2001-924171
                                                                   20010315 <--
     EP 1263756
                         В1
                                20040225
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR
     BR 2001009469
                                20030429
                                           BR 2001-9469
                                                                   20010315 <--
                         Α
     JP 2003528097
                          Τ
                                20030924
                                           JP 2001-568935
                                                                   20010315 <--
    AT 260272
                         Т
                               20040315
                                           AT 2001-924171
                                                                   20010315
    NZ 521245
                        Α
                               20040430
                                           NZ 2001-521245
                                                                   20010315
     ES 2215893
                         Т3
                               20041016
                                           ES 2001-924171
                                                                   20010315
     US 20020013341
                        A1
                              20020131
                                           US 2001-811116
                                                                   20010316 <--
     US 6495565
                         В2
                               20021217
     IN 2002MN01075
                               20050304
                                           IN 2002-MN1075
                                                                   20020808
                         Α
     HK 1049334
                               20040716
                                           HK 2003-101437
                                                                   20030226
                         Α1
PRIORITY APPLN. INFO.:
                                            US 2000-190183P
                                                               Ρ
                                                                 20000317
                                                               P 20000926
                                            US 2000-235467P
                                                               P 20001120
                                            US 2000-252062P
                                                               W 20010315
                                            WO 2001-US8336
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):
                        MARPAT 135:272894
    Novel \beta-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A =
     CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is
     absent or alkylene, alkenylene or alkynylene; Z is absent or substituted
     C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1
     [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a
     ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O,
     NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered
     heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted
     carbocycle or heterocycle), alkylene-Q, (CRaRa1)r10(CRaRa1)r-Q (r, r1 = \frac{1}{2}
     0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for
     Q), alkylene-Q1, (CRaRa1)r10(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.;
     R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and
     R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a
     stereoisomer or pharmaceutically acceptable salt were prepared as
     metalloprotease and TNF-\alpha inhibitors. Thus,
     N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-
     azetidinecarboxamide was prepared by a multistep procedure involving
     reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and
     3-azetidinecarboxylic acid Me ester. [This abstract record is one of 2
     records for this document necessitated by the large number of index entries
    required to fully index the document and publication system constraints.]
ΤТ
    362698-32-6P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of \beta-amino acid derivs. as inhibitors of matrix
        metalloproteases and TNF-\alpha)
     362698-32-6 CAPLUS
RN
```

Benzamide, N-[1-[2-(diethylamino)ethyl]-3-(hydroxyamino)-1-methyl-3-oxopropyl]-4-[(2-methyl-4-quinolinyl)methoxy]- (CA INDEX NAME)

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (11 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:713296 CAPLUS

DOCUMENT NUMBER: 135:272755

TITLE: Preparation of hydroxamic acids as inhibitors of

histone deacetylase

INVENTOR(S): Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii

PATENT ASSIGNEE(S): Methylgene, Inc., Can. SOURCE: PCT Int. Appl., 241 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PAT	CENT	NO.			KIN	KIND DATE A				APPLICATION NO.					DATE			
-	2001		-							WO 2	001-	IB68	3		2	0010	326 <	
WU	2001															_	_	
	W:	ΑE,	ΑG,	ΑL,	ΑM,	ΑT,	ΑU,	ΑZ,	ΒA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,	HR,	
		HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	
		LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MΖ,	NO,	NZ,	PL,	PT,	RO,	RU,	
		SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TR,	TT,	TZ,	UA,	UG,	UZ,	VN,	YU,	
		ZA,	ZW															
	RW:	GH,	GM,	KΕ,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
CA	2404	002			A1		2001	0927		CA 2	001-	2404	002		2	0010	326 <	
US	2002	0115	826		A1		2002	0822		US 2	001-	8173	74		2	0010	326 <	
US	7288	567			В2		2007	1030										
ΕP	1280	764			A2		2003	0205		EP 2	001-	9217:	35		2	0010	326 <	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2003528074 20030924 JP 2001-568887 20010326 <--Т EP 1524262 20050420 EP 2005-75122 20010326 Α1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR US 20090181971 20090716 US 2007-837696 Α1 20070813 PRIORITY APPLN. INFO.: US 2000-192151P P 20000324 EP 2001-921735 A3 20010326 US 2001-817374 A3 20010326 WO 2001-IB683 20010326

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 135:272755
GI

AB The title compds. CyXY1W [I; Cy = (un)substituted cycloalkyl, aryl, heterocyclyl; X = CO, CHOH, C:NOH, etc.; Y1 = (un)substituted alkylene, etc. (provided that Y1 does not comprise an ester or amide linkage in the linear chain connecting X and W); W = COCH2SR2, CONHOM, NHCONHZ, CONHZ (R2 = alkyl, aryl, aralkyl, acyl; M = H, cation; Z = hydroxyphenyl, pyridyl, thiazolyl, etc.)], useful for inhibiting histone deacetylase enzymic activity, and therefore for treating cell proliferative diseases and conditions, were prepared E.g., a multi-step synthesis of the title compound II which showed IC50 of 0.25 against recombinant human HDAC-1 enzyme, was given.

Ι

IT 362671-66-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxamic acids as inhibitors of histone deacetylase)

RN 362671-66-7 CAPLUS

CN Pentanamide, N-hydroxy-5-[methyl[2-(2-naphthalenyl)ethyl]amino]- (CA INDEX NAME)

OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

L19 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

10/923,271

ACCESSION NUMBER: 2001:667576 CAPLUS

DOCUMENT NUMBER: 136:43578

TITLE: Transition metal complexes of two new

imino-dihydroxamic acids

AUTHOR(S): Amelia Santos, M.; Grazina, R.; Pinto, M.; Farkas, E.

CORPORATE SOURCE: Centro de Quimica Estrutural, Instituto Superior

Tecnico, Lisbon, 1049-001, Port.

SOURCE: Inorganica Chimica Acta (2001), 321(1,2),

42 - 48

CODEN: ICHAA3; ISSN: 0020-1693

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal LANGUAGE: English

Two new iminodihydroxamic acids [N-benzyl-imino-bis(propionohydroxamic acid) and N-benzyl-imino-bis(butyrohydroxamic acid)] were prepared and studied as specific binders for the transition M2+ ions due to their potential interest as inhibitors of metalloproteinases. Their architecture is based on aliphatic backbones, as spacers connecting two hydroxamate chelating units, with an N-benzyl group inserted in that skeleton to simulate the protein lipophilic subset. Herein, we first report the synthetic procedure that basically involves the formation of the corresponding intermediates with two nitrile groups, which were then converted to the CONHOH moieties. Then, the acid-base and the chelating properties of these ligands towards Cu2+, Ni2+ and Zn2+ ions, studied by potentiometric and spectrophotometric techniques, are described. Both the ligands form quite stable complexes with these metal ions, presenting a preferential M2+ coordination to the hydroxamate over the amine groups, according to the order Zn2+ ≥ Ni2+ > Cu2+.

IT 380371-98-2D, transition metal complexes 380372-00-9D

, transition metal complexes

RL: CPS (Chemical process); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); FORM (Formation, nonpreparative); PROC (Process)

(transition metal complexation with imino-dihydroxamic acids)

RN 380371-98-2 CAPLUS

CN Propanamide, 3,3'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

RN 380372-00-9 CAPLUS

CN Butanamide, 4,4'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

IT 380371-98-2P 380372-00-9P

RL: CPS (Chemical process); PEP (Physical, engineering or chemical

process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(transition metal complexation with imino-dihydroxamic acids)

RN 380371-98-2 CAPLUS

CN Propanamide, 3,3'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

RN 380372-00-9 CAPLUS

CN Butanamide, 4,4'-[(phenylmethyl)imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:453016 CAPLUS

DOCUMENT NUMBER: 135:61071

TITLE: Preparation of hydroxamic acid derivatives as matrix

metalloproteinase (MMP) inhibitors

INVENTOR(S): Owen, David Alan; Baxter, Andrew Douglas; Watson,

Robert John; Montana, John Gary

PATENT ASSIGNEE(S): Darwin Discovery Ltd., UK SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIN	D DATE	APPLICATION NO.	DATE
WO 2001044188	A1	20010621	WO 2000-GB4861	20001218 <
W: AE, AG	AL, AM,	AT, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
CR, CU	CZ, DE,	DK, DM, DZ,	EE, ES, FI, GB, GD,	GE, GH, GM, HR,
HU, ID	IL, IN,	IS, JP, KE,	KG, KP, KR, KZ, LC,	LK, LR, LS, LT,
LU, LV	MA, MD,	MG, MK, MN,	MW, MX, MZ, NO, NZ,	PL, PT, RO, RU,
SD, SE	SG, SI,	SK, SL, TJ,	TM, TR, TT, TZ, UA,	UG, US, UZ, VN,
YU, ZA	ZW			
RW: GH, GM	KE, LS,	MW, MZ, SD,	SL, SZ, TZ, UG, ZW,	AT, BE, CH, CY,
DE, DK	ES, FI,	FR, GB, GR,	IE, IT, LU, MC, NL,	PT, SE, TR, BF,
BJ, CF	CG, CI,	CM, GA, GN,	GW, ML, MR, NE, SN,	TD, TG
AU 2001022017	A	20010625	AU 2001-22017	20001218 <
EP 1237867	A1	20020911	EP 2000-985609	20001218 <
R: AT, BE	CH, DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 6462042 B1 20021008 US 2001-806266 20010328 <-PRIORITY APPLN. INFO.: GB 1999-29979 A 19991217
WO 2000-GB4861 W 20001218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 135:61071

AB The title compds. B1NB2COCH2CR1R2CONHOH [I; R1 = alkyl, alkenyl, aryl, etc.; R2 = H, alkyl; CR1R2 = (un)substituted cycloalkyl, heterocycloalkyl; B1, B2 = H, alkyl, aryl, etc.] having therapeutic utility, were prepared E.g., a multi-step synthesis of (2S)-I [R1 = iso-Pr; R2 = H; B1 = Me; B2 = 4-(morpholin-4-yl)phenyl] was given. Compds. I are effective in treating inflammation at 0.01-50 mg/kg/day.

IT 345633-03-6P 345633-08-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxamic acid derivs. as matrix metalloproteinase (MMP) inhibitors)

RN 345633-03-6 CAPLUS

CN Butanediamide, N4-[2-(4-chlorophenoxy)ethyl]-N1-hydroxy-N4-methyl-2-(1-methylethyl)- (CA INDEX NAME)

RN 345633-08-1 CAPLUS

CN Butanediamide, N4-[3-(4-chlorophenyl)propyl]-N1-hydroxy-N4-methyl-2-(1-methylethyl)- (CA INDEX NAME)

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:441768 CAPLUS

DOCUMENT NUMBER: 133:74324

TITLE: Preparation of amino acid sulfonamide hydroxamates as

inhibitors of procollagen C-proteinase.

Billedeau, Roland Joseph; Broka, Chris Allen; INVENTOR(S): Campbell, Jeffrey Allen; Chen, Jian Jeffrey;

Dankwardt, Sharon Marie; Delaet, Nancy; Robinson,

Leslie Ann; Walker, Keith Adrian Murray

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

											LICAT					ATE		
											 1999-					 9991	214	<
	W:	ΑE,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	, BR,	BY,	CA,	CH,	CN,	CU,	CZ,	,
											, GM,							
											, LS,							
											, RU,							
											, ZA,		•	·	·			
	RW:										, UG,		AT,	BE,	CH,	CY,	DE,	,
											, MC,							
											, SN,			·	·	·	·	
CA	2355	902			A1		2000	0629		CA :	1999-	2355	902		1	9991	214	<
BR	9916	504			A		2001	0911		BR :	1999-	1650	4		1	9991	214	<
EP	1149	072			A1		2001	1031		EP :	1999-	9635	30		1	9991	214	<
EP	1149	072			В1		2004	0630			1999- 1999-							
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	,
		IE,	SI,	LT,	LV,	FI,	RO											
TR	2001	0018	68		T2		2001	1121		TR 2	2001-	1868			1	9991	214	<
HU	2001	0046	58		A2		2002	0629		HU 2	2001-	4658			1	9991	214	<
HU	2001	0046	58		А3		2005	1228										
JP	2001 2002 7693 5122 2702	5333	22		${ m T}$		2002	1008		JP 2	2000-	5895	08		1	9991	214	<
AU	7693	19			В2		2004	0122		AU 2	2000-	1979	2		1	9991	214	
NΖ	5122	92			A		2004	0326		NZ :	1999-	5122	92		1	9991	214	
ΑT	2702	271			T		2004	0715		AT 1	1999-	9635	30		1	9991	214	
RU	2232	751			C2		2004	0720		RU 2	2001-	1194	61		1	9991	214	
US	6492	394			В1		2002	1210		US :	1999-	4696	60		1	9991	222	<
HR	2001	0004	43		Α2		2002	0630		HR 2	2001- 2001- 2001- 2001-	443			2	0010	614	<
ZA	2001	0050	14		A A		2002	0919		ZA 2	2001-	5014			2	0010	619	<
MX	2001	.0063	28		A		2001	0910		MX 2	2001-	6328			2	0010	620	<
ИО	2001	0031			A		2001			NO 2	2001-	3100			2	0010	621	<
US	2003	0199	520		A1		2003	1023		US 2	2002-	2672	92		2	0021	009	<
	6844				В2		2005	0118										
US	2003	0216	405		A1		2003	1120		US 2	2002-	2677	27		2	0021	009	<
US	6787	559			В2		2004	0907										
ORIT	Y APF	·LN.	INFO	.:						US 3	1998-	1133	11P		P 1	9981	222	
										US 3	1998- 1999- 1999-	1470	53P		P 1	9990	803	
										US :	1999-	1641	38P		P 1	9991	108	
										WO :	1999-	EP99	20	,	W 1	9991	214	
										US :	1999-	4696	60		A3 1	9991	222	
TGNMI	ZNT F	ITSTO	RY F	OR II	S PA'	TENT	` A\/A	TLAB	LE T	N LS	SUS D	TSPL	AY F	ORMA	Т			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:74324

HOHNCOCHRINRSO2Ar2 [R1 = alkyl, haloalkyl, heteroalkyl, cycloalkyl, aryl,

08/09/2010 TOh

aralkyl, aralkenyl, heteroaryl, heteroaralkyl, aminl, aryl, aralkyl, etc.; R = CHR2Ar1, CHR2CH:CHAr1; Ar2 = specified (substituted) Ph, naphthyl; R2 = H, alkyl; with provisos], were prepared Thus, N-hydroxy-2(R)-[(3,4-methylenedioxybenzyl)(4-methoxy-2,3,6-trimethylbenzenesulfonyl)amino]-3-methylbutyramide was prepared by solution phase synthesis from BOC-D-Val-OH. Title compds. inhibited procollagen

IT 279255-20-8P 279255-52-6P

C-proteinase with IC50 0.01-2 μ M.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid sulfonamide hydroxamates as inhibitors of procollagen C-proteinase)

RN 279255-20-8 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]amino]-N5-ethyl-N1-hydroxy-N5-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 279255-52-6 CAPLUS

CN Pentanediamide, 2-[(1,3-benzodioxol-5-ylmethyl)][(4-methoxyphenyl)sulfonyl]amino]-N5-(2-cyanoethyl)-N1-hydroxy-N5-(phenylmethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (10 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 119 11-27 ibib abs hitstr

THE ESTIMATED COST FOR THIS REQUEST IS 98.77 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L19 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1998:498627 CAPLUS

DOCUMENT NUMBER: 129:175972

ORIGINAL REFERENCE NO.: 129:35769a,35772a

TITLE: Preparation of phenylsulfonamides as matrix

metalloproteinase inhibitors for treatment of diseases

INVENTOR(S): Takahashi, Kanji; Sugiura, Tsuneyuki

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Japan SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.

CODEN: JKXXAF

Ι

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

GI

TOh

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10204054 PRIORITY APPLN. INFO.:	A	19980804	JP 1997-20880 JP 1997-20880	19970121 <
	MADDAG	100 175070	JF 1997-20000	199/0121
OTHER SOURCE(S):	MARPAT	129:175972		

Phenylsulfonamides I [R1 = H, C1-4 alkyl; R2 = CO2R6, CONHOR7; R6, R7 = H, AB (un) substituted alkyl, Ph; R3 = OR11, (un) substituted amino, CO2R14, etc.; R11 = H, (un) substituted C1-4 alkyl, C2-4 acyl, etc; R14 = H, (un) substituted C1-4 alkyl, Ph; R4, R5 = H, (un) substituted C1-8 alky, (un) substituted amino, (hetero) cyclyl, etc.; E = CH:CH, C.tplbond.C; J = bond, C1-8 alkylene; R25 = H, (Ph-substituted) C1-4 alkyl, (Ph-substituted) alkoxycarbonyl] or their nontoxic salts are prepared The phenylsulfonamides are useful for treatment of rheumatoid arthritis, bone diseases, arteriosclerosis, tumor, autoimmune diseases, etc., caused by excess secretion or elevated activity of matrix metalloproteinase. Hydrolysis of N-[4-(4-hydroxy-1-butynyl)phenylsulfonyl]-D-tryptophan Me ester with aqueous NaOH gave 29% N-[4-(4-hydroxy-1-butynyl)phenylsulfonyl]-Dtryptophan, which inhibited gelatinase A activity at IC50 of 0.0079 μM . ΙT 211383-80-1P

08/09/2010

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylsulfonamides as matrix metalloproteinase inhibitors for treatment of diseases)

RN 211383-80-1 CAPLUS

CN Pentanediamide, N1-hydroxy-2-[[[4-(4-hydroxy-1-butyn-1-yl)phenyl]sulfonyl]amino]-N5-methyl-N5-(2-phenylethyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L19 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:805715 CAPLUS

DOCUMENT NUMBER: 128:61793

ORIGINAL REFERENCE NO.: 128:12110h, 12111a

TITLE: Preparation of N-(phenylsulfonyl)amino acid

derivatives as matrix metalloproteinase inhibitors

INVENTOR(S): Takahashi, Kanji; Sugiura, Tsuneyuki PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

ATEN	T NO.			KIN:	D	DATE			APPI	LICAT	ION NO.		DAT	E		
									WO 1	L997-	 JP1735		199	7052	 23 <	(
R	W: AT,	•	•	•		, ES,	ΓI,	FR,				•				
.U 97	27920			А												
_									-						_	
P 91	5086			A1		1999	0512		EP 1	L997-	922148		199	7052	23 <	(
R	: AT,	BE,	CH,	DE,	DK,	, ES,	FR,	GB,	GR,	IT,	LI, LU,	ΝL,	SE, P	Τ, Ι	ΙE,	FΙ
TY A	PPLN.	INFO	.:						JP 1	L996-	151864	Z	199	6052	24	
									JP 1	L997-	20879	Z	199	7012	21	
									WO 1	L997-	JP1735	V	√ 199	7052	23	
	O 97 W R U 97 P 10 P 91 R	W: AU, RW: AT, U 9727920 P 10265452 P 915086 R: AT,	O 9745402 W: AU, CA, RW: AT, BE, U 9727920 P 10265452 P 915086 R: AT, BE,	O 9745402 W: AU, CA, CN, RW: AT, BE, CH, U 9727920 P 10265452 P 915086	O 9745402 A1 W: AU, CA, CN, HU, RW: AT, BE, CH, DE, U 9727920 A P 10265452 A P 915086 A1 R: AT, BE, CH, DE,	O 9745402 A1 W: AU, CA, CN, HU, KR, RW: AT, BE, CH, DE, DK, DE, DK, DE, DK, DE, DK, A1 P 10265452 A P 915086 A1 R: AT, BE, CH, DE, DK, DK, DK, DK, DK, DK, DK, DK, DK, DK	O 9745402 A1 1997 W: AU, CA, CN, HU, KR, MX, RW: AT, BE, CH, DE, DK, ES, U 9727920 A 1998 P 10265452 A 1998 P 915086 A1 1999 R: AT, BE, CH, DE, DK, ES,	O 9745402 A1 19971204 W: AU, CA, CN, HU, KR, MX, NO, RW: AT, BE, CH, DE, DK, ES, FI, U 9727920 A 19980105 P 10265452 A 19981006 P 915086 A1 19990512 R: AT, BE, CH, DE, DK, ES, FR,	O 9745402 A1 19971204 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, U 9727920 A 19980105 P 10265452 A 19981006 P 915086 A1 19990512 R: AT, BE, CH, DE, DK, ES, FR, GB,	O 9745402 A1 19971204 WO 1 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, U 9727920 A 19980105 AU 1 P 10265452 A 19981006 JP 1 P 915086 A1 19990512 EP 1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, TY APPLN. INFO.: JP 1	O 9745402 A1 19971204 WO 1997- W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, U 9727920 A 19980105 AU 1997- P 10265452 A 19981006 JP 1997- P 915086 A1 19990512 EP 1997- R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, TY APPLN. INFO.: JP 1996- JP 1997-	O 9745402 A1 19971204 WO 1997-JP1735 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, U 9727920 A 19980105 AU 1997-27920 P 10265452 A 19981006 JP 1997-148448 P 915086 A1 19990512 EP 1997-922148 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, TY APPLN. INFO.: JP 1996-151864 JP 1997-20879	O 9745402 A1 19971204 WO 1997-JP1735 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, U 9727920 A 19980105 AU 1997-27920 P 10265452 A 19981006 JP 1997-148448 P 915086 A1 19990512 EP 1997-922148 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, TY APPLN. INFO.: JP 1996-151864 A JP 1997-20879	O 9745402 A1 19971204 WO 1997-JP1735 199 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, N U 9727920 A 19980105 AU 1997-27920 199 P 10265452 A 19981006 JP 1997-148448 199 P 915086 A1 19990512 EP 1997-922148 199 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, P TY APPLN. INFO.: JP 1996-151864 A 199 JP 1997-20879 A 199	O 9745402 A1 19971204 WO 1997-JP1735 1997052 W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, F U 9727920 A 19980105 AU 1997-27920 1997052 P 10265452 A 19981006 JP 1997-148448 1997052 P 915086 A1 19990512 EP 1997-922148 1997052 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, TY APPLN. INFO.: JP 1996-151864 A 1996052 JP 1997-20879 A 1997012	O 9745402 A1 19971204 WO 1997-JP1735 19970523 < W: AU, CA, CN, HU, KR, MX, NO, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, U 9727920 A 19980105 AU 1997-27920 19970523 < P 10265452 A 19981006 JP 1997-148448 19970523 < P 915086 A1 19990512 EP 1997-922148 19970523 < R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, TY APPLN. INFO.: JP 1996-151864 A 19960524

OTHER SOURCE(S): MARPAT 128:61793

GΙ

$$\begin{array}{c} \text{R}^1 \\ \text{SO}_2 \text{NR}^2 \text{O}_{\text{CR}} \text{9}_{\text{R}} \text{10}_{\text{R}} \text{2} \\ \\ \text{A-J-E} \end{array}$$

AΒ Phenylsulfonylamide derivs. represented by general formula (I; R1 = hydrogen or alkyl; R2 = CO2R3 or CONHOR4; wherein R3 = H, C1-8 alkyl, Ph, substituted C1-4 alkyl; R4 = H, C1-8 alkyl, Ph, phenyl-C1-4 alkyl; E =CH:CH, C.tplbond.C; A = hydrogen, alkyl, (un) substituted carbocycle or heterocycle; J = single bond or alkylene; R9, R10 = each hydrogen, (substituted) alkyl, COR11, carbocycle, heterocycle, etc.; R11 = OH, C1-8 alkyl, C1-8 alkoxy, PhO, phenyl-C1-4 alkyl, (un)substituted NH2; R20 = hydrogen, (substituted) C1-4 alkyl, C1-8 alkoxycarbonyl, phenyl-C1-4 alkoxycarbonyl, substituted C1-8 alkyl; or NR20CR9 = 5- to 7-membered heterocyclic ring containing 1 N atom) and salts thereof are prepared Also claimed are processes for producing the same; a matrix metalloproteinase inhibitor containing the same; and medicines containing the same and serving as preventives and/or remedies for rheumatism, osteoarthritis, pathol. bone resorption, osteoporosis, periodontosis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, hepatocirrhosis, corneal injury, diseases due to cancer cell metastasis, infiltration and proliferation, autoimmune diseases (such as Crohn's disease and Sjogren's disease), diseases due to leukocyte emigration or infiltration, and neovascularization. Thus, 4-bromobenzenesulfonyl chloride was added to a solution of tert-Bu D-phenylalaninate in pyridine under ice-cooling and the resulting mixture was stirred at room temperature for 1 h to give tert-Bu N-(4-bromophenylsulfonyl)-D-phenylalaninate. A mixture of the latter compound, 10% Pd-C, Ph3P, CuI, MeCN, and Et3N was refluxed for 3 h to give tert-Bu D-phenylalaninate derivative (II; R = tert-butyl) which was stirred at room temperature for 1 h to give II (R = H). A tablet and an ampule formulation

containing II (R = H) were prepared

IT 200294-53-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(phenylsulfonyl)amino acid derivs. as matrix metalloproteinase inhibitors for disease treatment)

RN 200294-53-7 CAPLUS

CN Pentanediamide, N1-hydroxy-N5-methyl-2-[[[4-[2-(4-methylphenyl)ethynyl]phenyl]sulfonyl]amino]-N5-(2-phenylethyl)-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS

RECORD (24 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:506187 CAPLUS

DOCUMENT NUMBER: 122:242807

ORIGINAL REFERENCE NO.: 122:44327a,44330a TITLE: Preparation of

3-[bis(carboxymethyl)amino]-N-hydroxypropionamides and

salts and their use as sequestering agents

INVENTOR(S): Greindl, Thomas; Kud, Alexander; Schwendemann, Volker;

Kneip, Michael; Kappes, Elisabeth; Baur, Richard; Schneider, Juergen; Potthoff-karl, Birgit; Oftring,

Alfred

PATENT ASSIGNEE(S): BASF A.-G., Germany SOURCE: Ger. Offen., 10 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	TENT NO.			KINI)	DATE		API	PLICAT	ION NO	٥.	Ι	DATE		
	4313137			A1	_		1027		1993-		_		.9930		
WO	9424096 W: CA,	JP,	US	A1		1994	1027	WO	1994-	EPI16	б	_	.9940	415	<
מיז	RW: AT,	BE,	CH,	DE, A1	DK,			GB, GI EP					PT, .9940		
	695289			B1		1998		LF	1994-	91013	9	_	. 9940	±13	\
	R: DE,	•	GB,		NL					E00E4	_	_			
	08508746			T		1996			1994-	~	_		.9940		
	5733342 APPLN.	INFO	.:	A		1998	U331	DE	1995- 1993- 1994-	43131	37	A 1	.9951 .9930 .9940	122	<

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 122:242807

AB Sequestering agents (XO2CCH2)2NCHR1CHR2CONHOY (R1-2 = H, Me, Et; X, Y = H, alkali metal, ammonium) are prepared for use as detergent builders and bleach stabilizers. Iminodiacetic acid, Me acrylate, H2NOH, and NaOH were used in the preparation of (HO2CCH2)2NCH2CH2CONHOH mono-Na salt which was used (5 parts) with 30 parts zeolite A in a laundry detergent composition which

inhibited incrustations in fabrics during repeated laundering.

IT 162459-81-6P 162459-83-8P

RL: IMF (Industrial manufacture); MOA (Modifier or additive use); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(sequestering agents; preparation and use as detergent builders and bleach

stabilizers)

RN 162459-81-6 CAPLUS

CN Glycine, N-(carboxymethyl)-N-[3-(hydroxyamino)-3-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Na

RN 162459-83-8 CAPLUS

CN Glycine, N-(carboxymethyl)-N-[3-(hydroxyamino)-3-oxopropyl]-, disodium salt (9CI) (CA INDEX NAME)

●2 Na

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L19 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:700765 CAPLUS

DOCUMENT NUMBER: 121:300765

ORIGINAL REFERENCE NO.: 121:55057a,55060a

TITLE: Preparation of oxoheterocyclyl-substituted hydroxamic

acid derivatives as collagenase inhibitors
INVENTOR(S): Broadhurst, Michael John; Brown, Paul Anthony;

Johnson, William Henry; Lawton, Geoffrey

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 574758	A1	19931222	EP 1993-108628	19930528 <

EP 574758	B1	19980909			
R: AT, BE	, CH, DE, DK	E, ES, FR,	GB, GR, IE, IT, LI,	LU, M	C, NL, PT, SE
US 5318964	A	19940607	US 1993-66832		19930524 <
AU 9339816	A	19931216	AU 1993-39816		19930526 <
AU 659555	В2	19950518			
AT 170840	T	19980915	AT 1993-108628		19930528 <
ES 2121896	Т3	19981216	ES 1993-108628		19930528 <
ZA 9303957	A	19931213	ZA 1993-3957		19930604 <
RO 112613	В3	19971128	RO 1993-777		19930604 <
CZ 283373	В6	19980415	CZ 1993-1081		19930604 <
IL 105921	A	19980104	IL 1993-105921		19930607 <
CA 2098168	A1	19931212	CA 1993-2098168		19930610 <
NO 9302117	A	19931213	NO 1993-2117		19930610 <
CN 1083062	A	19940302	CN 1993-107239		19930610 <
CN 1035616	С	19970813			
JP 06065196	A	19940308	JP 1993-165228		19930610 <
JP 07076210	В	19950816			
FI 109535	B1	20020830	FI 1993-2692		19930611 <
US 5447929	A	19950905	US 1994-214895		19940317 <
PRIORITY APPLN. INF	0.:		GB 1992-12421	A	19920611
			GB 1993-5720	А	19930319
			US 1993-66832	А3	19930524

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT OTHER SOURCE(S): MARPAT 121:300765

GΙ

AB R1(CH2)nCH(CONHOH)CH(CONR2R3)CHR4CR5R6CH2R7 (R1 = N-attached oxoheterocyclyl; R2 = alkyl; R3 = alkyl or aryl; NR2R3 = heterocyclyl; R4-R7 = H or Me; n = 1-4) were prepared Thus, (2R)-[(1R,S)-tert-butoxycarbonyl-2-phthalimidoethyl]-4-methylvaleric acid was amidated by 1-benzyloxycarbamoyl-(3S)-hexahydropyridazinecarboxylic acid and the product converted in 3 steps to title compound (R,S)-I which had IC50 of 1.2 nM against collagenase in vitro.

IT 159135-28-1P 159135-30-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as collagenase inhibitor)

RN 159135-28-1 CAPLUS

CN Hexanamide, 1-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N,N-diethyl-N'-

hydroxy-5-methyl- (CA INDEX NAME)

RN 159135-30-5 CAPLUS

CN Hexanamide, 1-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-ethyl-N'-hydroxy-N,5-dimethyl- (CA INDEX NAME)

OS.CITING REF COUNT: 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)

L19 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:578813 CAPLUS

DOCUMENT NUMBER: 121:178813

ORIGINAL REFERENCE NO.: 121:32467a,32470a

TITLE: Convenient method for the preparation of some

polyhydroxamic acids: Michael addition of amines to

acrylohydroxamic acid derivatives

AUTHOR(S): Koshti, Nirmal M.; Jacobs, Hollie K.; Martin, Patrick

A.; Smith, Paul H.; Gopalan, Aravamudan S.

CORPORATE SOURCE: Dep. Chem. and Biochem., New Mexico State Univ., Las

Cruces, NM, 88003-8001, USA

SOURCE: Tetrahedron Letters (1994), 35(29), 5157-60

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 121:178813

AB Reagents CH2:CHCONR1OR2 (R1 = H, R2 = PhCH2; R1 = Me, R2 = SiMe2CMe3, SiPh2CMe3) are readily prepared by the reaction of the appropriate hydroxylamine derivs. with acryloyl chloride. The reagents undergo Michael addition with a variety of amines to give the corresponding O-protected hydroxamate derivs. in moderate to good yields. Subsequent removal of the protecting group provides a convenient method for the preparation of a number of mono-, di-, tri- and tetrahydroxamic acids.

IT 157614-62-5P 157614-64-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 157614-62-5 CAPLUS

CN Propanamide, 3,3'-[[3-[[3-(hydroxyamino)-3-

oxopropyl]methylamino]propyl]imino]bis[N-hydroxy- (9CI) (CA INDEX NAME)

O
$$CH_2-CH_2-C-NH-OH$$
 O $||$ HO-NH-C-CH₂-CH₂-N-(CH₂)3-N-CH₂-CH₂-C-NH-OH $|$ Me

RN 157614-64-7 CAPLUS

CN Propanamide, 3,3'-[1,6-hexanediylbis(methylimino)]bis[N-hydroxy- (9CI) (CA INDEX NAME)

OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L19 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:420632 CAPLUS

DOCUMENT NUMBER: 121:20632

ORIGINAL REFERENCE NO.: 121:3711a,3714a

TITLE: Minimization and remediation of DOE nuclear waste

problems using high selectivity actinide chelators

AUTHOR(S): Gopalan, A.; Zincircioqlu, O.; Smith, P.

CORPORATE SOURCE: Dep. Chem., New Mexico State Univ., Las Cruces, NM,

88003, USA

SOURCE: Radioactive Waste Management and the Nuclear Fuel

Cycle (1993), 17(3-4), 161-75

CODEN: RWMCD4; ISSN: 0739-5876

DOCUMENT TYPE: Journal LANGUAGE: English

AB The goal of this research program is to design, develop, and synthesize organic chelators for selective binding of actinide ions from soils and waste streams. A thorough assessment has been made of available chelators/ligands known or suspected to have high affinities and selectivities for actinides. Based upon the authors' studies in addition to the well studied catecholates, multidentate oxoligands such as hydroxamate, iminodiacetate, and hydroxypyridinones show promise for binding relatively hard actinide ions present in acidic, aqueous process solns. Some specific model chelating structures for plutonium ion binding have been identified for synthesis and study of their binding abilities. In these mols., the ligand groups are preorganized around a template/spacer group, to coordinate the target metal ion specifically.

Chelators that have been synthesized contain either a flexible acyclic structural backbone or a rigid benzene spacer to which the ligands are appended. Also, methods for the preparation of some model hexadentate and octadentate hydroxamate chelators and a novel chelator containing three iminodiacetic acid ligands are described. Results of some preliminary binding studies on the synthesized chelators are discussed. Desferrioxamine-B, a known hydroxamic acid siderophore, has been used a model to develop procedures for evaluating the binding abilities of synthetic chelators.

IT 155819-25-3

RL: PROC (Process)

(chelating agent, for actinide removal from contaminated soils and radioactive wastewaters)

RN 155819-25-3 CAPLUS

CN Propanamide, 3,3',3'',3'''-(1,3-propanedinitrilo)tetrakis[N-hydroxy-, tetrapotassium salt (9CI) (CA INDEX NAME)

● 4 K

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L19 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:307465 CAPLUS

DOCUMENT NUMBER: 120:307465

ORIGINAL REFERENCE NO.: 120:53941a,53944a

TITLE: Hydroxamic acid-based bifunctional chelating compounds INVENTOR(S): Safavy, Ahmad; Buchsbaum, Donald J.; Khazaeli, M. B.

PATENT ASSIGNEE(S): UAB Research Foundation, USA

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND DATE		AE	PPLICATI	ON NO.	1	DATE
WO 9405627		A1	19940317	WC	O 1993-U	JS8401		19930907 <
W: AT,	AU, BB,	BG, BR	, BY, CA,	CH, C	CZ, DE,	DK, ES,	FI, GB	, HU, JP,
KP,	KR, KZ,	LK, LU	, LV, MG,	MN, N	MW, NL,	NO, NZ,	PL, PT	, RO, RU,
SD,	SE, SK,	UA, VN						

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5756825 Α US 1993-48869 19930416 <--19980526 AU 9348501 Α 19940329 AU 1993-48501 19930907 <--PRIORITY APPLN. INFO.: US 1992-941986 Α 19920908 US 1993-48869 Α 19930416 WO 1993-US8401 W 19930907

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

The present disclosure details the preparation of hydroxamic acid-based bifunctional chelators and their use in conjugating metal ions to proteins and nucleic acids for tumor or tissue imaging or therapy purposes. Some preferred aspects of the disclosure involve the preparation of trisuccin, particularly useful for binding radionuclides such as 99Tc, 186Re, and 67Cu. Thus, trisuccin-monoclonal antibody CC49 conjugate was prepared using dicyclohexylcarbodiimide and labeled with 99mTc. The radiolabeled conjugate was administered to human colon cancer cell line-bearing mice and the tumor localization and tissue biodistribution of the antibodies were determined

ΤT 155109-50-5

RL: BIOL (Biological study)


(as bifunctional chelator for conjugation of metal ions to proteins)

RN 155109-50-5 CAPLUS

L-Glutamine, N2, N2-bis[3-(hydroxyamino)-3-oxopropyl]-N-hydroxy-, CN

2-oxoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

1994:211240 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 120:211240

ORIGINAL REFERENCE NO.: 120:37301a,37304a

TITLE: Design and synthesis of new peptidase inhibitors based

on an endogenous ACE inhibitor Val-Trp

AUTHOR(S):

Ueki, Masaaki; Katoh, Tsuyoshi; Shimizu, Tatsuto; Komiya, Satoko; Tobe, Masanori; Mizuno, Mamoru; Yuasa,

Ritsuko; Watanabe, Ayako; Hazato, Tadahiko

CORPORATE SOURCE: Dep. Appl. Chem., Sci. Univ. Tokyo, Tokyo, 162, Japan

Pept. Chem. 1992, Proc. Jpn. Symp., 2nd (1993***), Meeting Date 1992, 538-40. Editor(s): Yanaihara, SOURCE:

Noboru. ESCOM: Leiden, Neth.

CODEN: 59NTAC

DOCUMENT TYPE: Conference LANGUAGE: English


AB Using the naturally occurring angiotensin-converting enzyme (ACE) inhibitor, Val-Trp, as a lead compd., and adding a hydroxamate group which is a key Zn-interacting structure in kelatorphin, an inhibitor of enkephalin-degrading enzymes, a synthetic ACE and enkephalinase A and B inhibitor, SUT-9014, was designed, prepd., and tested. Using SUT-9014 [N-(RS)-[2-(hydroxyaminocarbonyl)-3-methyl-1-oxobutyl]-L-tryptophan] as a 2nd lead compd., 12 analogs were synthesized and structure-activity relations were studied. The results indicated that the amino H atom of tryptophan is necessary for enzyme recognition by the H-bond and that the structure of the P2' site appeared to be more important in ACE.

TT ***153980-96-2, SUT 9132 RL: BIOL (Biological study)

(angiotensin-converting enzyme and enkephalinases A and B inhibition by, structure in relation to)

RN 153980-96-2 CAPLUS

CN Glycine, N-[2-[(hydroxyamino)carbonyl]-3-methyl-1-oxobutyl]-N-(1H-indol-3-ylmethyl)- (CA INDEX NAME)



L19 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1993:21976 CAPLUS

DOCUMENT NUMBER: 118:21976

ORIGINAL REFERENCE NO.: 118:4129a,4132a

TITLE: Novel tetrahydroxamate chelators for actinide complexation: synthesis and binding studies AUTHOR(S): Gopalan, Aravamudan S.; Huber, Vincent J.;

Zincircioglu, Orhan; Smith, Paul H.

CORPORATE SOURCE: Dep. Chem., New Mexico State Univ., Las Cruces, NM,

88003-0001, USA

SOURCE: Journal of the Chemical Society, Chemical

Communications (1992), (17), 1266-8

CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: Journal LANGUAGE: English

AB The chelators, e.g., 1,3-C6H4[CH2N(CH2CH2CONHOH)2]2, members of a new class of tetrahydroxamate chelators, are readily synthesized and are shown by potentiometric studies to have high affinities for thorium(IV), iron(III) and neodymium(III).

IT 145060-17-9P 145060-18-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, protonation consts. and formation consts. of, for metal

08/09/2010

chelation)
RN 145060-17-9 CAPLUS

TOh

CN Propanamide, 3,3',3'',3'''-[1,3-phenylenebis(methylenenitrilo)]tetrakis[N-hydroxy-, tripotassium salt (9CI) (CA INDEX NAME)

●3 K

RN 145060-18-0 CAPLUS

CN Propanamide, 3,3',3'',3'''-[1,4-phenylenebis(methylenenitrilo)]tetrakis[N-hydroxy-, tripotassium salt (9CI) (CA INDEX NAME)

●3 K

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L19 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1992:407618 CAPLUS

DOCUMENT NUMBER: 117:7618

ORIGINAL REFERENCE NO.: 117:1539a,1542a

TITLE: General method for the synthesis of trishydroxamic

acids

AUTHOR(S): Karunaratne, V.; Hoveyda, H. R.; Orvig, C.

CORPORATE SOURCE: Dep. Chem., Univ. British Columbia, Vancouver, BC, V6T

1Z1, Can.

SOURCE: Tetrahedron Letters (1992), 33(14), 1827-30

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 117:7618

10/923,271

AB Triscarboxylic acids, when treated with hydroxylamines in the presence of water-soluble carbodiimide in THF-H2O, at pH .apprx. 4.8, yield the corresponding trishydroxamic acids in good yields.

IT 69778-14-9P

RN 69778-14-9 CAPLUS

CN Propanamide, 3,3',3''-nitrilotris[N-hydroxy- (9CI) (CA INDEX NAME)

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD

(3 CITINGS)

L19 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1984:531205 CAPLUS

DOCUMENT NUMBER: 101:131205

ORIGINAL REFERENCE NO.: 101:19977a,19980a

TITLE: Role of complex formation during polycondensation of activated N-hydroxysuccinimide esters with diamines

AUTHOR(S): Katsarava, R. D.; Kharadze, D. P.; Avalishvili, L. M.;

Zaalishvili, M. M.

CORPORATE SOURCE: Inst. Fiziol., Tbilisi, USSR

SOURCE: Vysokomolekulyarnye Soedineniya, Seriya A (

1984), 26(7), 1537-43

CODEN: VYSAAF; ISSN: 0507-5475

DOCUMENT TYPE: Journal LANGUAGE: Russian

GΙ

AB During polycondensation of diamines with the title esters (I, Z = alkylene, arylene), the N-hydroxysuccinimide (II) [6066-82-6] byproduct formed complexes with the diamines. During polycondensation of weakly reactive I (Z = arylene) with aliphatic diamines at moderate temps., the complexation retarded polycondensation and prevented formation of high-mol.-weight polyamides. The polymerization rate increased sharply at higher

temperature; however, side reactions also intensified. During reaction of

highly reactive I ($\mathbf{Z} = \mathbf{alkylene}$), complexation had little influence on the polymerization

IT 91990-28-2P

RL: PREP (Preparation)

(formation and properties of, polycondensation of diamines with hydroxysuccinimide diesters in relation to)

RN 91990-28-2 CAPLUS

CN Butanediamide, N1, N1-diethyl-N4-hydroxy- (CA INDEX NAME)

L19 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1983:18481 CAPLUS

DOCUMENT NUMBER: 98:18481
ORIGINAL REFERENCE NO.: 98:2973a,2976a

TITLE: Hydroxamic acid amphoteric surfactants

PATENT ASSIGNEE(S): Lion Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57119997	A	19820726	JP 1981-6137	19810119 <
JP 62053510	В	19871110		
PRIORITY APPLN. INFO.:			JP 1981-6137	19810119

AB Et 3-[N-(2-hydroxyethyl)-N-(lauroylaminoethyl)amino]propionate [83952-04-9] (47.9 G) was dissolved in 200 g EtOH, mixed with 10 g NH2OH·HCl [5470-11-1] and 12 g NaOH, and stirred for 1-5 h to prepare 45 g 3-[N-(2-hydroxyethyl)-N-(lauroylaminoethyl)amino]propiohydroxamic acid (I) [83952-05-0] which was an inhibitor for urease [9002-13-5]. A solution containing 0.75% I inhibited >60% of the formation of NH3.

IT 83952-05-0P

RL: TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(surfactants, amphoteric, manufacture of, as inhibitors for urease)

RN 83952-05-0 CAPLUS

CN Dodecanamide, N-[2-[[3-(hydroxyamino)-3-oxopropy1](2hydroxyethy1)amino]ethy1]- (CA INDEX NAME)

L19 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:145712 CAPLUS

DOCUMENT NUMBER: 90:145712

ORIGINAL REFERENCE NO.: 90:23037a,23040a

TITLE: The selection and evaluation of new chelating agents

for the treatment of iron overload

AUTHOR(S): Pitt, C. G.; Gupta, G.; Estes, W. E.; Rosenkrantz, H.;

Metterville, J. J.; Crumbliss, A. L.; Palmer, R. A.;

Nordquest, K. W.; Sprinkle Hardy, K. A.; et al.

CORPORATE SOURCE: Res. Triangle Inst., Research Triangle Park, NC, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics

(1979), 208(1), 12-18

CODEN: JPETAB; ISSN: 0022-3565

DOCUMENT TYPE: Journal LANGUAGE: English

AB A large-scale systematic evaluation of potential iron chelators for the treatment of hemosiderosis was conducted. The compds. were identified and evaluated using a hypertransfused mouse screen in which deferrioxamine B [70-51-9] was a standard This screen was designed to measure Fe depletion in the tissues as well as Fe excretion. Groups of 10 previously hypertransfused BDF1 male mice received a single daily i.p. injection of either vehicle, standard, or test compound for 7 days. Fe in daily urine pools

and individual spleen and liver homogenates was determined by atomic

absorption.

More than 70 chelators were evaluated, including natural and synthetic hydroxamic acids, phenols, catechols and tropolones known to have a high affinity for Fe (III) in vitro. Ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) [1170-02-1] was considerable more effective than deferrioxamine B (i.p.) and, in addition, was orally active. Factors determining the efficacy of this and other chelating agents are discussed.

IT 69778-14-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (iron chelation by, in hemosiderosis)

RN 69778-14-9 CAPLUS

CN Propanamide, 3,3',3''-nitrilotris[N-hydroxy- (9CI) (CA INDEX NAME)

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L19 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:102966 CAPLUS

DOCUMENT NUMBER: 90:102966

ORIGINAL REFERENCE NO.: 90:16255a,16258a

TITLE: Dipolar micelles. 8. Hydrolysis of substituted

phenyl esters in a hydroxamic acid surfactant

AUTHOR(S): Pillersdorf, A.; Katzhendler, J.

Sch. Pharm., Hebrew Univ., Jerusalem, Israel CORPORATE SOURCE: SOURCE: Journal of Organic Chemistry (1979), 44(4),

549 - 54

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal LANGUAGE: English

The reactions of hydroxamic acid catalysts of the structure Me(CH2)nN+Me2(CH2)3CONHOH Br-[n = 15 (I), 0] with substituted Ph esters were studied. The kinetics in I followed the expression: kobsd = ko + kcka/(ka + H+) + kOH[OH-]. The water-catalysis rates ko for all the esters studied were significantly greater than the spontaneous rate consts. reported in the literature for esters with identical leaving groups. The magnitude of the water rate consts., and their dependence on microenvironmental factors as displayed by mixed micellar systems, indicated that the reaction proceeds via electrophilic assistance by the onium head groups. Nucleophilic attack by the hydroxamate anion (kc) in I on the esters corresponds to a β Broensted value of -1.1. Although I was expected to be an α -effector catalyst, the relative enhancement of the rate consts. was very small. This was explained in terms of proximity and electrostatic effects in the transition state. The basic-hydrolysis rates kOH and the titrimetric behavior of I were also discussed.

ΙT 68367-35-1P

> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and catalysis by, of hydrolysis of substituted Ph esters, kinetics with)

68367-35-1 CAPLUS RN

CN 1-Hexadecanaminium, N-[4-(hydroxyamino)-4-oxobutyl]-N, N-dimethyl-, bromide (1:1) (CA INDEX NAME)

Br -

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L19 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

1973:38037 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 78:38037 ORIGINAL REFERENCE NO.: 78:5949a,5952a

Potential hypotensive compounds. Substituted TITLE:

3-aminopropionates and 3-aminopropionohydroxamic acids Biggs, D. F.; Coutts, R. T.; Selley, M. L.; Towill, G. AUTHOR(S):

CORPORATE SOURCE: Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB,

SOURCE: Journal of Pharmaceutical Sciences (1972),

61(11), 1739-45

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal LANGUAGE: English

AB Most of the 48 3-aminoproprionate esters studied were synthesized by addition of an amine across the α, β -double bond of Me acrylate [96-33-3], Me methacrylate [80-62-6], or Me crotonate [18707-60-3], while the remainder were obtained by interaction of 1 mole of a 3-bromopropionic ester with 2 moles of the corresponding amine. Twenty-six 3-aminopropionohydroxamic acid hydrochlorides were prepared by treatment of the appropriate amino ester with hydroxylamine-HCl [5470-11-1] in MeOH. Many of the compds. such as 2-methyl-3-[(2-phenylethyl)amino]propanoic acid Me ester [6297-67-2], 3,3'-[(2-phenylethyl)imino]bispropanoic acid dimethyl ester [38129-46-3], N-[3-(hydroxyamino)-2-methyl-3oxopropyl]heptanaminium chloride [38129-47-4], and N-[3-(hydroxyamino)-3-oxopropy1]-2-(2-phenylethy1) benzeneethanaminium chloride [38202-84-5] possessed hypotensive properties but of very short duration. 2-Methyl-3-(octylamino)propanoic acid Me ester [29228-46-4] was the most active, and at 4 mg/kg i.v. decreased the blood pressure of rats by an average of 52% for 12 min. Some of the compds. were screened for their ability to protect mice against a lethal dose of

diisopropylfluorophosphate [55-91-4], but none was active.

ΙT 38202-84-5P

> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and hypotensive effect of)

RN 38202-84-5 CAPLUS

Propanamide, 3-[bis(2-phenylethyl)amino]-N-hydroxy-, hydrochloride (1:1) CN (CA INDEX NAME)

● HCl

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L19 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1971:75986 CAPLUS

DOCUMENT NUMBER: 74:75986

ORIGINAL REFERENCE NO.: 74:12327a,12330a

TITLE: Synthesis and properties of some hypotensive

N-alkylaminopropionic esters and

N, N-dialkylaminopropionic esters and their hydroxamic

acids

AUTHOR(S): Coutts, Ronald T.; Hubbard, J. W.; Midha, Kamal K.;

Prasad, Kailash

CORPORATE SOURCE: Fac. Pharm. Pharm. Sci., Univ. Alberta, Edmonton, AB,

Can.

SOURCE: Journal of Pharmaceutical Sciences (1971),

60(1), 28-33

CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Thirty-eight 3-(N-alkylamino)- and 3-(N,N-dialkylamino)propionic esters (I), hydroxamic acids (II), carboxylic acids, and related compds. were synthesized and the majority of the esters and hydroxamic acids decreased the blood pressure of anesthetized cats, while the carboxylic acids were inactive. The esters were prepared by the interaction of methyl acrylate or methyl methacrylate and an appropriate amine. Some hindered amines did not react with the acrylate, and some esters hydrolyzed to the corresponding carboxylic acids when stored even for a short time. The hydroxamic acids were prepared from the amino esters treated with hydroxylamine.

IT 31035-63-9P 31035-64-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 31035-63-9 CAPLUS

CN Propanamide, 3-(diethylamino)-N-hydroxy-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} & \text{O} \\ & | & || \\ \text{Et}_2\text{N--} \text{CH}_2\text{--} \text{CH--} \text{C---} \text{NH--} \text{OH} \end{array}$$

● HCl

RN 31035-64-0 CAPLUS

CN Propanamide, 3-(dipropylamino)-N-hydroxy-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)

● HCl

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L19 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1964:483943 CAPLUS

DOCUMENT NUMBER: 61:83943

ORIGINAL REFERENCE NO.: 61:14578h,14579a-c

TITLE: Synthesis and polarographic reduction of aliphatic

amino hydroxamic acids

AUTHOR(S): Matveev, B. V.; Tsybaeva, G. G.

CORPORATE SOURCE: S. M. Kirov Milit. Med. Acad., Leningrad

SOURCE: Zhurnal Obshchei Khimii (1964), 34(8),

2491 - 5

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal LANGUAGE: Unavailable

AB The hydroxamic acids listed below were prepared from esters of appropriate amino acids and HONH2.HCl in H2O or aqueous EtOH at $0-10^{\circ}$; they were isolated as HCl salts after evaporation and extraction with hot EtOH; the HCl salts

were converted to the free acids with EtONa solution, and further treatment with MeI gave the corresponding methiodides. For these acids, the % yields, m.p., pKa and polarographic half-wave potentials (volts) were as follows: AcNHOH, 45, 85°, 8.70, -2.18; H2NCH2CONHOH.HCl, 60, 108-9°, 7.35, -2.33; Me2NCH2CONHOH.HCl, 50, 145°, 7.10, -2.10; Me3NCH2CONHOH.Br, 52, 156°, 6.70, -2.38; Et2NCH2CONHOH.HCl, 44, 11819°, 7.20, -2.10; Et3NCH2CONHOH.Br, 31, 141-3°, 6.60, -2.12; H2NCHMeCONHOH.HCl, 52, 165°, 7.25, -2.35; Me2NCHMeCONOH.HCl, 51, 170-1°, 6.80, -2.28; Me3NCHMeCONHOH.I, 72, 80-1°, 6.65, -2.45; H2NCH2CH2CONHOH.HCl, 20, 144°, 7.90, -2.30; Me2NCH2CH2CONHOH.HCl, 82, 90-1°, 7.85, -2.25; Me3NCH2CH2CONHOH.I, 73, 133-4°, 8.0, -2.22; Et2NCH2CH2CONHOH.HC1, 77, 91-2°, 8.15, -2.20; 2NCH2CH2CONHOH.HC1, 50, 80-1°, 8.40, -2.22; Me3NCH2CH2CONHOH.Br, 33, 163-5°, 8.60, -2.22; PhCH2NMe2CH2CONHOH.Br, 43, -, 6.70, -2.15; PhCH2NMe2CH2CH2CONHOH.Br, 41, -, 8.40, -2.19; HO2CCH(NH2)CH2CH2CONHOH.HCl, 43, 114, -, -2.18; MeSCH2CH2CH(NH2)CONHOH.HCl, 61, 130-2°, 6.60, -2.17; CH2[CH2NMe2CH2CONHOH]2.2Br, 47, -, 6.20, -2.36. The correlation of the half-wave potentials with dissociation consts. is discussed.

91773-87-4P, Propionohydroxamic acid, 3-(diethylamino)-,
hydrochloride

91773-87-4 CAPLUS

CN Propanamide, 3-(diethylamino)-N-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)

RN

● HCl